AAAP Документы SEC - Advanced Accelerator Applications S.A- Годовой отчет, доверенное заявление, проспект эмиссии

Основная статистика

CIK

1611787

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Advanced Accelerator Applications S.A

SEC Filings (Chronological Order)

На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.

February 26, 2019	SC 13G/A	AAAP / Advanced Accelerator Applications S.A / Fin Posillipo S.p.A. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Advanced Accelerator Applications S.A. (Name of Issuer) Ordinary Shares, nominal value €.10 per share, and American Depositary Shares, each representing two (2) Ordinary Shares (Title of Class of Securities) 00790T100** (CUSIP Number) December 31, 2018
February 14, 2018	SC 13G/A	AAAP / Advanced Accelerator Applications S.A / PRICE T ROWE ASSOCIATES INC /MD/ - AAAP AS OF 12/31/2017 Passive Investment SC 13G/A 1 aaap13gadec17.htm AAAP AS OF 12/31/2017 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) ADVANCED ACCELERATOR APPLICATIONS S.A. (Name of Issuer) ORDINARY SHARES AMERICAN DEPOSITARY SHARES (Title of Class of Securities) 00790T100* (CUSIP Number) December 31, 2017 (Date of Event which Requi
February 12, 2018	15-12B	AAAP / Advanced Accelerator Applications S.A 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-36826 Advanced Accelerator Applications S.A. (Exact name of registrant a
February 9, 2018	S-8 POS	AAAP / Advanced Accelerator Applications S.A FORM S-8 POS As filed with the Securities and Exchange Commission on February 9, 2018 Registration No.
February 9, 2018	S-8 POS	AAAP / Advanced Accelerator Applications S.A FORM S-8 POS As filed with the Securities and Exchange Commission on February 9, 2018 Registration No.
February 1, 2018	EX-99.(A)(5)(E)	MEDIA RELEASE · COMMUNIQUE AUX MEDIAS · MEDIENMITTEILUNG Exhibit (a)(5)(E) Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.
February 1, 2018	SC TO-T/A	NVS / Novartis AG SC TO-T SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) Advanced Accelerator Applications S.A. (Name of Subject Company) by Novartis Groupe France S.A. and Novartis AG (Name of Filing Persons (Offerors)) Ordinary Shares, par value ?0.10 per share (Title of Class of Sec
February 1, 2018	SC 14D9/A	AAAP / Advanced Accelerator Applications S.A SC 14D9/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) (Amendment No. 5) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ADVANCED ACCELERATOR APPLICATIONS S.A. (Name of Subject Company) ADVANCED ACCELERATOR APPLICATIONS S.A. (Name of Person(s) Filing Statement) Ordinary shares, par value ?0.10 per share (?Ordinary
February 1, 2018	6-K	AAAP / Advanced Accelerator Applications S.A 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2018 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Ad
February 1, 2018	EX-99.1	Advanced Accelerator Applications Announces Completion of Subsequent Offering Period for Novartis Tender Offer Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Announces Completion of Subsequent Offering Period for Novartis Tender Offer February 1, 2018, Saint-Genis-Pouilly, France - Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (?AAA? or the ?Company?), a Novartis company and a leader in nuclear medicine theragnostics, today announced that a subsidiary of Novartis AG (NYSE: NVS) (?Novar
February 1, 2018	25	AAAP / Advanced Accelerator Applications S.A 25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-36826 Advanced Accelerator Applications S.A. The NASDAQ Global Select Market (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed an
February 1, 2018	SC 13D	AAAP / Advanced Accelerator Applications S.A / NOVARTIS AG - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Advanced Accelerator Applications S.A. (Name of Issuer) Ordinary shares, par value €0.10 per share (“Ordinary Shares”) American Depositary Shares, each of which represents 2 Ordinary Shares, par value €0.10 per share (Title of Class of Securities) F0R0DZ103 00790T100** (CU
February 1, 2018	EX-1	JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated February 1, 2018, with respect to the ordinary shares, nominal value €0.
January 30, 2018	SC 13G/A	AAAP / Advanced Accelerator Applications S.A / Levi Andrea Ruben Osvaldo - FORM SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. 2 Advanced Accelerator Applications S.A. (Name of Issuer) Ordinary Shares, par value €0.10 per share (Title of Class of Securities) 00790T100* (CUSIP Number) January 22, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to
January 30, 2018	SC 13G/A	AAAP / Advanced Accelerator Applications S.A / Buono Stefano - FORM SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. 2 Advanced Accelerator Applications S.A. (Name of Issuer) Ordinary Shares, par value €0.10 per share (Title of Class of Securities) 00790T100* (CUSIP Number) January 22, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to
January 26, 2018	EX-99.1	Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors First-in-class Therapy Demonstrated 79% Improvement in Progression Free Survival in NETTER-1 Phase 3 Study in Midg Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA? for Treatment of Gastroenteropancreatic Neuroendocrine Tumors First-in-class Therapy Demonstrated 79% Improvement in Progression Free Survival in NETTER-1 Phase 3 Study in Midgut NET Patients LUTATHERA? marks first FDA Approval for a Peptide Receptor Radionuclide Therapy (PRRT) January 26, 2018, Sa
January 26, 2018	6-K	AAAP / Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp856456k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Sai
January 22, 2018	SC 14D9/A	AAAP / Advanced Accelerator Applications S.A SC 14D9/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) (Amendment No. 4) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ADVANCED ACCELERATOR APPLICATIONS S.A. (Name of Subject Company) ADVANCED ACCELERATOR APPLICATIONS S.A. (Name of Person(s) Filing Statement) Ordinary shares, par value ?0.10 per share (?Ordinary
January 22, 2018	6-K	AAAP / Advanced Accelerator Applications S.A 6-K (Current Report of Foreign Issuer) 6-K 1 a18-354126k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint
January 22, 2018	EX-99.1	Advanced Accelerator Applications Announces Completion of $3.9 Billion Novartis Tender Offer Novartis Global Oncology Expertise to Enhance Launch of Lutetium Lu 177 Dotatate (LUTATHERA®) and Accelerate Development of Theragnostic Pipeline Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Announces Completion of $3.9 Billion Novartis Tender Offer Novartis Global Oncology Expertise to Enhance Launch of Lutetium Lu 177 Dotatate (LUTATHERA?) and Accelerate Development of Theragnostic Pipeline January 22, 2018, Saint-Genis-Pouilly, France - Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (?AAA? or the ?Company?), a leade
January 22, 2018	EX-99.(A)(5)(D)	MEDIA RELEASE • COMMUNIQUE AUX MEDIAS • MEDIENMITTEILUNG Exhibit 99.(a)(5)(D) Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com MEDIA RELEASE ? COMMUNIQUE AUX MEDIAS ? MEDIENMITTEILUNG Novartis completes tender offer for Advanced Accelerator Applications S.A. and announces commencement of subsequent offering period ? Transaction expands Novartis Oncology neuroendocrine tumor (NET) treatment portfo
January 22, 2018	SC TO-T/A	NVS / Novartis AG SC TO-T SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) Advanced Accelerator Applications S.A. (Name of Subject Company) by Novartis Groupe France S.A. and Novartis AG (Name of Filing Persons (Offerors)) Ordinary Shares, par value ?0.10 per share (Title of Class of Sec
January 12, 2018	EX-99.(E)(16)	[AAA Letterhead] [·], 2018 Exhibit (e)(16) STRICTLY CONFIDENTIAL FORM OF RETENTION AGREEMENT FOR U.S. AND OTHER EMPLOYEES [AAA Letterhead] [?], 2018 [Recipient] [Recipient Address] [Recipient Address] Dear [Recipient]: As you are aware, Advanced Accelerator Applications S.A. (the ?Company?) entered into a Memorandum of Understanding with Novartis AG (?Novartis?), dated as of October 28, 2017 (the ?MoU?), pursuant to which N
January 12, 2018	EX-99.(E)(17)	SERVICES AGREEMENT Exhibit (e)(17) Execution Version SERVICES AGREEMENT This SERVICES AGREEMENT (this ?Agreement?), dated as of January 11, 2018 (the ?Execution Date?), is entered into by and between Novartis Pharma AG (?Novartis Pharma?), a wholly owned subsidiary of Novartis AG (the ?Parent?), and Stefano Buono (the ?Consultant?).
January 12, 2018	SC 14D9/A	AAAP / Advanced Accelerator Applications S.A SC 14D9/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) (Amendment No. 3) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ADVANCED ACCELERATOR APPLICATIONS S.A. (Name of Subject Company) ADVANCED ACCELERATOR APPLICATIONS S.A. (Name of Person(s) Filing Statement) Ordinary shares, par value ?0.10 per share (?Ordinary
January 12, 2018	EX-99.(E)(18)	SERVICES AGREEMENT Exhibit (e)(18) Execution Version SERVICES AGREEMENT This SERVICES AGREEMENT (this ?Agreement?), dated as of January 11, 2018 (the ?Execution Date?), is entered into by and between Novartis Pharma AG (?Novartis Pharma?), a wholly owned subsidiary of Novartis AG (the ?Parent?), and G?rard Ber (the ?Consultant?).
January 12, 2018	EX-99.(D)(8)	SERVICES AGREEMENT Exhibit (d)(8) SERVICES AGREEMENT This SERVICES AGREEMENT (this Agreement), dated as of January 11, 2018 (the Execution Date), is entered into by and between Novartis Pharma AG (Novartis Pharma), a wholly owned subsidiary of Novartis AG (the Parent), and Stefano Buono (the Consultant).
January 12, 2018	EX-99.(D)(9)	SERVICES AGREEMENT Exhibit (d)(9) SERVICES AGREEMENT This SERVICES AGREEMENT (this ?Agreement?), dated as of January 11, 2018 (the ?Execution Date?), is entered into by and between Novartis Pharma AG (?Novartis Pharma?), a wholly owned subsidiary of Novartis AG (the ?Parent?), and G?rard Ber (the ?Consultant?).
January 12, 2018	SC TO-T/A	NVS / Novartis AG SC TO-T/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) Advanced Accelerator Applications S.A. (Name of Subject Company) by Novartis Groupe France S.A. and Novartis AG (Name of Filing Persons (Offerors)) Ordinary Shares, par value ?0.10 per share (Title of Class of Sec
January 8, 2018	EX-99.(A)(1)(S)	Advanced Accelerator Applications, s.a. au capital 8 851 565,70 Euros 20, rue Diesel, 01630 Saint Genis Pouilly, France- tel. +33 4 50 99 30 70 — fax +33 4 50 99 30 71 — www.adacap.com N° Siret: 441 417 110 00026 - 441417110 RCS Bourg en Bresse - N° Exhibit 99.(a)(1)(S) By email Paris, [ ], 20[ ] Subject: Novartis Groupe France S.A.?s tender offer on Advanced Accelerator Applications S.A. Dear Shareholder: As you may have heard, on December 7, 2017, Advanced Accelerator Applications (?AAA?) announced that Novartis AG?s subsidiary, Novartis Groupe France S.A., commenced a cash tender offer (the ?Offer?) to purchase all of the outstanding ordin
January 8, 2018	SC 14D9/A	AAAP / Advanced Accelerator Applications S.A SC 14D9/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) (Amendment No. 2) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ADVANCED ACCELERATOR APPLICATIONS S.A. (Name of Subject Company) ADVANCED ACCELERATOR APPLICATIONS S.A. (Name of Person(s) Filing Statement) Ordinary shares, par value ?0.10 per share (?Ordinary
December 22, 2017	SC 14D9/A	AAAP / Advanced Accelerator Applications S.A SC 14D9/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) (Amendment No. 1) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ADVANCED ACCELERATOR APPLICATIONS S.A. (Name of Subject Company) ADVANCED ACCELERATOR APPLICATIONS S.A. (Name of Person(s) Filing Statement) Ordinary shares, par value ?0.10 per share (?Ordinary
December 22, 2017	CORRESP	AAAP / Advanced Accelerator Applications S.A CORRESP New York Northern California Washington DC São Paulo London Paris Madrid Tokyo Beijing Hong Kong John G.
December 21, 2017	SC TO-T/A	NVS / Novartis AG SC TO-T SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) Advanced Accelerator Applications S.A. (Name of Subject Company) by Novartis Groupe France S.A. and Novartis AG (Name of Filing Persons (Offerors)) Ordinary Shares, par value ?0.10 per share (Title of Class of Sec
December 7, 2017	6-K	AAAP / Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp838676k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2017 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Sa
December 7, 2017	EX-99.1	Advanced Accelerator Applications Announces Commencement of Novartis Tender Offer Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Announces Commencement of Novartis Tender Offer December 7, 2017, Saint-Genis-Pouilly, France - Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a leader in nuclear medicine theragnostics, today announced that a direct and indirect subsidiary of Novartis AG (NYSE: NVS), Novartis Groupe France S.A., a soci?t? ano
December 7, 2017	EX-99.(A)(1)(D)	AAA Shareholder or LTI Plan Participant Tender Participation Guide Exhibit 99(a)(1)(D) AAA Shareholder or LTI Plan Participant Tender Participation Guide Introduction Dear Madam / Sir, As a holder of ordinary shares, stock options warrants of Advanced Accelerator Applications S.
December 7, 2017	EX-99.(E)(13)	EMPLOYMENT AGREEMENT Exhibit 99.(e)(13) EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of 1 July 2016 (the “Effective Date”), by and between AAA Switzerland, S.A., a limited company (Société anonyme) organized and existing under the laws of Switzerland (the “Company”), and Gerard Ber (the “Executive”). The Company and Executive are referred to herein collectively as the “Parties”,
December 7, 2017	EX-99.(E)(11)	EMPLOYMENT AGREEMENT Exhibit 99.(e)(11) EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of 1 July 2016 (the “Effective Date”), by and between Advanced Accelerator Applications, S.A., a public limited company (Société anonyme) organized and existing under the laws of France (the “Company”), and Stefano Buono (the “Executive”). The Company and Executive are referred to herein collect
December 7, 2017	EX-99.(D)(3)	accountants, financial advisors, agents and other representatives of such person and its affiliates In consideration of your being provided with Confidential Information and being offered the opportunity to evaluate the business and operations of the Exhibit 99(d)(3) Exhibit (d)(3) CONFIDENTIALITY AGREEMENT August 22, 2017 Novartis International AG Lichtstrasse 35 4056 Basel Switzerland Attention: Head Legal M&A Ladies and Gentlemen: In connection with your consideration of a possible acquisition of Advanced Accelerator Applications S.
December 7, 2017	EX-99.(A)(1)(Q)	[AAA Letterhead] Exhibit 99.(a)(1)(Q) [AAA Letterhead] [Name / address of holder] By international courier service and email December 7, 2017 Object: waiver of your right to your non-vested free shares in exchange for a cash payment Dear Sir / Madam, On December 5, 2017, Advanced Accelerator Applications S.A. (the “Company”) announced that it recommended the cash tender offer by Novartis Groupe France S.A., a soci
December 7, 2017	EX-99.(A)(1)(O)	[AAA Letterhead] Exhibit 99.(a)(1)(O) [AAA Letterhead] [Name / address of holder] By international courier service and email December 7, 2017 Object: notification of your right to exercise your stock options Dear Sir / Madam, On December 5, 2017, Advanced Accelerator Applications S.A. (the “Company”) announced that it recommended the cash tender offer by Novartis Groupe France S.A., a société anonyme organized und
December 7, 2017	EX-99.(A)(1)(K)	the Company's name or otherwise, and with any amendments, including amendments of substance), including the Agreements, that the Attorneys may deem necessary or advisable in connection with the Transaction (the "Appointment"). 2.The Appointment shall Exhibit 99(a)(1)(k) Exhibit (a)(l)(K) POWER OF ATTORNEY THIS POWER OF ATTORNEY is made this )0t" day of October, 2017 by Novartis AG, a company incorporated under the laws of Switzerland, with its registered office located at Lichtstrasse 35, 4056 Basel (the "Company").
December 7, 2017	EX-99.(1)(1)(A)	OFFER TO PURCHASE FOR CASH ALL OF THE OUTSTANDING ORDINARY SHARES INCLUDING ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES OF ADVANCED ACCELERATOR APPLICATIONS S.A. FOR U.S. $41.00 PER ORDINARY SHARE AND U.S. $82.00 PER AMERICAN DEPOSITARY Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Exhibit 99(a)(1)(A) OFFER TO PURCHASE FOR CASH ALL OF THE OUTSTANDING ORDINARY SHARES INCLUDING ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES OF ADVANCED ACCELERATOR APPLICATIONS S.
December 7, 2017	EX-99.(A)(1)(J)	assumptions, certificates, deeds, notices, instruments, amendments, documents, filings or any other additional writings or communications whatsoever (whether under hand or seal or as a deed and in the Company's name or otherwise, and with any amendme Exhibit 99(a)(1)(J) Exhibit (a)(l)(J) POWER OF ATTORNEY THIS POWER OF ATTORNEY is made this 23'' day of November 2017 by Mr.
December 7, 2017	EX-99.(A)(1)(P)	[AAA Letterhead] Exhibit 99.(a)(1)(P) [AAA Letterhead] [Name / address of holder] By international courier service and email December 7, 2017 Object: exercise of your warrants Dear Sir / Madam, On December 5, 2017, Advanced Accelerator Applications S.A. (the “Company”) announced that it recommended the cash tender offer by Novartis Groupe France S.A., a société anonyme organized under the laws of France and a dire
December 7, 2017	EX-99.(A)(5)(A)	MEDIA RELEASE · COMMUNIQUE AUX MEDIAS · MEDIENMITTEILUNG Exhibit 99(a)(5)(a) Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.
December 7, 2017	EX-99.(D)(6)	[Remainder of page intentionally left blank; signature page follows] Exhibit 99(d)(6) STRICTLY CONFIDENTIAL October 28, 2017 Dear G?rard: In our capacity as possible future controlling shareholder of Advanced Accelerator Applications S.
December 7, 2017	EX-99.(A)(1)(F)	OFFER TO PURCHASE FOR CASH ALL OF THE OUTSTANDING ORDINARY SHARES INCLUDING ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES OF ADVANCED ACCELERATOR APPLICATIONS S.A. PURSUANT TO THE OFFER TO PURCHASE DATED DECEMBER 7, 2017 BY NOVARTIS GROUP QuickLinks - Click here to rapidly navigate through this document Exhibit 99(a)(1)(F) OFFER TO PURCHASE FOR CASH ALL OF THE OUTSTANDING ORDINARY SHARES INCLUDING ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES OF ADVANCED ACCELERATOR APPLICATIONS S.
December 7, 2017	EX-99.(A)(1)(R)	Advanced Accelerator Applications, s.a. au capital 8 851 565,70 Euros 20, rue Diesel, 01630 Saint Genis Pouilly, France- tel. +33 4 50 99 30 70 – fax +33 4 50 99 30 71 – www.adacap.com N° Siret: 441 417 110 00026 - 441417110 RCS Bourg en Bresse - N° Exhibit 99.(a)(1)(R) By international courier service and/or email Paris, December 7, 2017 Subject: Novartis Groupe France S.A.’s tender offer on Advanced Accelerator Applications S.A. Dear Sir/Madam, On December 5, 2017, Advanced Accelerator Applications S.A. (“AAA”) announced that it has recommended the cash tender offer by Novartis Groupe France S.A., a société anonyme organized under the laws
December 7, 2017	EX-99.(D)(7)	[Signature Page for BUONO Letter] Exhibit 99(d)(7) STRICTLY CONFIDENTIAL October 28, 2017 Dear Stefano: In our capacity as possible future controlling shareholder of Advanced Accelerator Applications S.
December 7, 2017	EX-99.(E)(14)	Restrictive Covenants Exhibit 99.(e)(14) STRICTLY CONFIDENTIAL October 28, 2017 Dear Stefano: In our capacity as possible future controlling shareholder of Advanced Accelerator Applications S.A. (441 417 110 RCS Bourg-en-Bresse) (?AAA?) following the Closing (as defined below), we are pleased to confirm the attached terms, on the terms and conditions set forth in this letter agreement. 1. Your services under this lette
December 7, 2017	EX-99.(E)(2)	[Signature pages follow] Exhibit 99.(e)(2) EXECUTION VERSION December 5, 2017 Novartis AG Postfach CH-4002 Basel Switzerland Attention: Head of M&A Legal Re: First Amendment to the Memorandum of Understanding Dear Ladies and Gentlemen: Reference is hereby made to that certain Memorandum of Understanding dated as of October 28, 2017 (as amended, restated, supplemented or otherwise modified from time to time, the “Memorandu
December 7, 2017	EX-99.(E)(5)	[Signature pages follow] Exhibit 99.(e)(5) EXECUTION VERSION December 6, 2017 Novartis AG Postfach CH-4002 Basel Switzerland Attention: Head of M&A Legal Re: First Amendment to the Tender and Support Agreements Dear Ladies and Gentlemen: Reference is hereby made to the following Tender and Support Agreements, dated as of October 28, 2017 (each as amended, restated, supplemented or otherwise modified from time to time, a “
December 7, 2017	EX-99.(A)(1)(M)	Advanced Accelerator Applications Announces Commencement of Novartis Tender Offer Exhibit 99.(a)(1)(M) PRESS RELEASE Advanced Accelerator Applications Announces Commencement of Novartis Tender Offer December 7, 2017, Saint-Genis-Pouilly, France - Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a leader in nuclear medicine theragnostics, today announced that a direct and indirect subsidiary of Novartis AG (NYSE: NVS), Novartis Groupe France S.A., a soc
December 7, 2017	EX-99.(A)(1)(H)	NOTICE OF GUARANTEED DELIVERY TO TENDER FOR CASH ALL OF THE OUTSTANDING ORDINARY SHARES INCLUDING ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES OF ADVANCED ACCELERATOR APPLICATIONS S.A. PURSUANT TO THE OFFER TO PURCHASE DATED DECEMBER 7, QuickLinks - Click here to rapidly navigate through this document Exhibit 99(a)(1)(H) NOTICE OF GUARANTEED DELIVERY TO TENDER FOR CASH ALL OF THE OUTSTANDING ORDINARY SHARES INCLUDING ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES OF ADVANCED ACCELERATOR APPLICATIONS S.
December 7, 2017	EX-99.(A)(1)(G)	OFFER TO PURCHASE FOR CASH ALL OF THE OUTSTANDING ORDINARY SHARES INCLUDING ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES OF ADVANCED ACCELERATOR APPLICATIONS S.A. PURSUANT TO THE OFFER TO PURCHASE DATED DECEMBER 7, 2017 BY NOVARTIS GROUP QuickLinks - Click here to rapidly navigate through this document Exhibit 99(a)(1)(G) OFFER TO PURCHASE FOR CASH ALL OF THE OUTSTANDING ORDINARY SHARES INCLUDING ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES OF ADVANCED ACCELERATOR APPLICATIONS S.
December 7, 2017	SC TO-T	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ADVANCED ACCELERATOR APPLICATIONS S.A. (NAME OF SUBJECT COMPANY (ISSUER)) NOVARTIS QuickLinks - Click here to rapidly navigate through this document SECURITIES AND EXCHANGE COMMISSION Washington, D.
December 7, 2017	EX-99.(A)(1)(C)	ORDINARY SHARE ACCEPTANCE FORM TO TENDER ORDINARY SHARES ADVANCED ACCELERATOR APPLICATIONS S.A. U.S. $41.00 PER ORDINARY SHARE PURSUANT TO THE OFFER TO PURCHASE DATED DECEMBER 7, 2017 NOVARTIS GROUPE FRANCE S.A. A DIRECT AND INDIRECT WHOLLY-OWNED SUB QuickLinks - Click here to rapidly navigate through this document Exhibit 99(a)(1)(C) ORDINARY SHARE ACCEPTANCE FORM TO TENDER ORDINARY SHARES OF ADVANCED ACCELERATOR APPLICATIONS S.
December 7, 2017	EX-99.(A)(1)(E)	LETTER OF TRANSMITTAL TO TENDER AMERICAN DEPOSITARY SHARES OF ADVANCED ACCELERATOR APPLICATIONS S.A. AT U.S. $82.00 PER AMERICAN DEPOSITARY SHARE PURSUANT TO THE OFFER TO PURCHASE DATED DECEMBER 7, 2017 BY NOVARTIS GROUPE FRANCE S.A. A DIRECT AND IND QuickLinks - Click here to rapidly navigate through this document Exhibit 99(a)(1)(E) LETTER OF TRANSMITTAL TO TENDER AMERICAN DEPOSITARY SHARES OF ADVANCED ACCELERATOR APPLICATIONS S.
December 7, 2017	EX-99.(A)(1)(I)	Notice of Offer to Purchase for Cash All of the Outstanding Ordinary Shares Ordinary Shares Represented by American Depositary Shares Advanced Accelerator Applications S.A. U.S. $41.00 Per Ordinary Share U.S. $82.00 Per American Depositary Share Nova Exhibit 99(a)(1)(I) This announcement is not an offer to purchase or a solicitation of an offer to sell Ordinary Shares or ADSs (each as defined below).
December 7, 2017	EX-99.(E)(12)	EMPLOYMENT AGREEMENT Exhibit 99.(e)(12) EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of 1 July 2016 (the “Effective Date”), by and AAA Switzerland, S.A., a limited company (Société anonyme) organized and existing under the laws of Switzerland (the “Company”), and Heinz Mäusli (the “Executive”). The Company and Executive are referred to herein collectively as the “Parties”, and e
December 7, 2017	EX-99.(E)(4)	TENDER AND SUPPORT AGREEMENT Exhibit 99.(e)(4) TENDER AND SUPPORT AGREEMENT THIS TENDER AND SUPPORT AGREEMENT (this “Agreement”) is entered into as of October 28, 2017, by and between Novartis AG, a company organized under the laws of Switzerland (“Parent”) and [ ] (“Shareholder”). RECITALS A. Parent and Advanced Accelerator Applications S.A., a société anonyme organized under the laws of France (the “Company”) are entering i
December 7, 2017	SC 14D9	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ADVANCED ACCELERATOR APPLICATIONS S.A. (Name of Subject Compan Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.
December 7, 2017	EX-99.(D)(4)	TENDER AND SUPPORT AGREEMENT Exhibit 99(d)(4) TENDER AND SUPPORT AGREEMENT THIS TENDER AND SUPPORT AGREEMENT (this ?Agreement?) is entered into as of October 28, 2017, by and between Novartis AG, a company organized under the laws of Switzerland (?Parent?) and [ ] (?Shareholder?).
December 7, 2017	EX-99.(A)(1)(B)	By international courier service and/or email QuickLinks - Click here to rapidly navigate through this document Exhibit 99(a)(1)(B) By international courier service and/or email Paris, December 7, 2017 Subject: Novartis Groupe France S.
December 7, 2017	EX-99.(E)(15)	[Signature Page for BER Letter] Exhibit 99.(e)(15) STRICTLY CONFIDENTIAL October 28, 2017 Dear G?rard: In our capacity as possible future controlling shareholder of Advanced Accelerator Applications S.A. (441 417 110 RCS Bourg-en-Bresse) (?AAA?) following the Closing (as defined below), we are pleased to confirm the attached terms, on the terms and conditions set forth in this letter agreement. 1. Your services under this letter
December 7, 2017	EX-99.(D)(5)	[Signature pages follow] Exhibit 99(d)(5) EXECUTION VERSION December 6, 2017 Novartis AG Postfach CH-4002 Basel Switzerland Attention: Head of M&A Legal Re: First Amendment to the Tender and Support Agreements Dear Ladies and Gentlemen: Reference is hereby made to the following Tender and Support Agreements, dated as of October 28, 2017 (each as amended, restated, supplemented or otherwise modified from time to time, a ?Tender and Support Agreement,? and collectively, the ?Tender and Support Agreements?), by and between Novartis AG (?Parent?) and (i) Stefano Buono, (ii) G?rard Ber, (iii) Claudio Costamagna, (iv) CC & Soci S.
December 7, 2017	EX-99.(D)(2)	[Signature pages follow] Exhibit 99(d)(2) EXECUTION VERSION December 5, 2017 Novartis AG Postfach CH-4002 Basel Switzerland Attention: Head of M&A Legal Re: First Amendment to the Memorandum of Understanding Dear Ladies and Gentlemen: Reference is hereby made to that certain Memorandum of Understanding dated as of October 28, 2017 (as amended, restated, supplemented or otherwise modified from time to time, the ?Memorandum of Understanding?), by and between Novartis AG (?Parent?) and Advanced Accelerator Applications S.
December 5, 2017	EX-99.1	Advanced Accelerator Applications Board of Directors Recommends $3.9 Billion All Cash Tender Offer by Novartis Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Board of Directors Recommends $3.9 Billion All Cash Tender Offer by Novartis December 5, 2017, Saint-Genis-Pouilly, France - Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a leader in nuclear medicine theragnostics, today announced that its Board of Directors, following the completion of the information and co
December 5, 2017	6-K	AAAP / Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp838686k2.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2017 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 S
December 5, 2017	SC14D9C	AAAP / Advanced Accelerator Applications S.A FORM SC14D9C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ADVANCED ACCELERATOR APPLICATIONS S.A. (Name of Subject Company) ADVANCED ACCELERATOR APPLICATIONS S.A. (Name of Person(s) Filing Statement) Ordinary shares, par value ?0.10 per share (?Ordinary Shares?) American
December 5, 2017	EX-99.1	Advanced Accelerator Applications Board of Directors Recommends $3.9 Billion All Cash Tender Offer by Novartis EX-99.1 2 dp83857ex9901.htm EXHIBIT 99.1 Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Board of Directors Recommends $3.9 Billion All Cash Tender Offer by Novartis December 5, 2017, Saint-Genis-Pouilly, France - Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a leader in nuclear medicine theragnostics, today announced that its Board of Directors, following
November 23, 2017	EX-99.1	The acquisition of AAA "shows we recognize the excellence of France" (translation, Interview with Bruno Strigini) EX-99.1 2 a2233921zex-991.htm EX-99.1 QuickLinks - Click here to rapidly navigate through this document Exhibit 99.1 This is a translation of an interview with Bruno Strigini, Head of the Oncology Division at Novartis, originally published in French in the French newspaper La Tribune on November 22, 2017 The acquisition of AAA "shows we recognize the excellence of France" (translation, Interview w
November 23, 2017	SC TO-C	NVS / Novartis AG SC TO-C QuickLinks - Click here to rapidly navigate through this document SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 17, 2017	SC14D9C	AAAP / Advanced Accelerator Applications S.A FORM SC14D9C SC14D9C 1 dp83030sc14d9c.htm FORM SC14D9C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ADVANCED ACCELERATOR APPLICATIONS S.A. (Name of Subject Company) ADVANCED ACCELERATOR APPLICATIONS S.A. (Name of Person(s) Filing Statement) Ordinary shares, par value €0
November 17, 2017	EX-99.1	Advanced Accelerator Applications Reports 39% Sales Growth for Third Quarter 2017 $3.9 Billion All Cash Proposed Tender Offer by Novartis European Approval of Lutetium Lu 177 Dotatate* (Lutathera®) for GEP-NETs Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Reports 39% Sales Growth for Third Quarter 2017 $3.9 Billion All Cash Proposed Tender Offer by Novartis European Approval of Lutetium Lu 177 Dotatate* (Lutathera?) for GEP-NETs Recent Highlights: ? Sales for the third quarter of 2017 increased 39% compared to the third quarter of 2016 ? NETSPOT? unit sales per month increased 14% (from 9
November 17, 2017	EX-99.1	Advanced Accelerator Applications Reports 39% Sales Growth for Third Quarter 2017 $3.9 Billion All Cash Proposed Tender Offer by Novartis European Approval of Lutetium Lu 177 Dotatate* (Lutathera®) for GEP-NETs Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Reports 39% Sales Growth for Third Quarter 2017 $3.9 Billion All Cash Proposed Tender Offer by Novartis European Approval of Lutetium Lu 177 Dotatate* (Lutathera?) for GEP-NETs Recent Highlights: ? Sales for the third quarter of 2017 increased 39% compared to the third quarter of 2016 ? NETSPOT? unit sales per month increased 14% (from 9
November 17, 2017	6-K	AAAP / Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2017 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Ad
November 17, 2017	EX-99.2	Advanced Accelerator Applications S.A. 20 rue Rudolf Diesel 01630 Saint Genis Pouilly IFRS CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Nine months and three months ended September 30, 2017 and 2016 EX-99.2 3 dp82822ex9902.htm EXHIBIT 99.2 EXHIBIT 99.2 Advanced Accelerator Applications S.A. Advanced Accelerator Applications S.A. 20 rue Rudolf Diesel 01630 Saint Genis Pouilly IFRS CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Nine months and three months ended September 30, 2017 and 2016 1 Advanced Accelerator Applications S.A. CONDENSED CONSOLIDATED STATEMENTS OF INCOME Nine Months and
October 30, 2017	EX-99.1	Advanced Accelerator Applications Announces $3.9 Billion All Cash Proposed Tender Offer by Novartis Novartis Oncology Expertise to Facilitate Ongoing Development of Theragnostic Pipeline Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Announces $3.9 Billion All Cash Proposed Tender Offer by Novartis Novartis Oncology Expertise to Facilitate Ongoing Development of Theragnostic Pipeline October 30, 2017, Saint-Genis-Pouilly, France - Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a leader in nuclear medicine theragnostics, today announced tha
October 30, 2017	SC14D9C	Advanced Accelerator Applications S.A FORM SC14D9C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ADVANCED ACCELERATOR APPLICATIONS S.A. (Name of Subject Company) ADVANCED ACCELERATOR APPLICATIONS S.A. (Name of Person(s) Filing Statement) Ordinary shares, par value ?0.10 per share (?Ordinary Shares?) American
October 30, 2017	EX-99.1	Advanced Accelerator Applications Announces $3.9 Billion All Cash Proposed Tender Offer by Novartis Novartis Oncology Expertise to Facilitate Ongoing Development of Theragnostic Pipeline Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Announces $3.9 Billion All Cash Proposed Tender Offer by Novartis Novartis Oncology Expertise to Facilitate Ongoing Development of Theragnostic Pipeline October 30, 2017, Saint-Genis-Pouilly, France - Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a leader in nuclear medicine theragnostics, today announced tha
October 30, 2017	EX-99.2	MEMORANDUM OF UNDERSTANDING BY AND BETWEEN Novartis AG Advanced Accelerator Applications S.A. DATED AS OF OCTOBER 28, 2017 EX-99.2 3 dp82115ex9902.htm EXHIBIT 99.2 Exhibit 99.2 EXECUTION VERSION MEMORANDUM OF UNDERSTANDING BY AND BETWEEN Novartis AG AND Advanced Accelerator Applications S.A. DATED AS OF OCTOBER 28, 2017 1 TABLE OF CONTENTS Page Article I DEFINITIONS Section 1.1 Specific Definitions 1 Section 1.2 Interpretation 12 Article II THE OFFER Section 2.1 Announcements 2 Section 2.2 Offer 12 Section 2.3 Company
October 30, 2017	6-K	Advanced Accelerator Applications S.A F0RM 6-K (Current Report of Foreign Issuer) 6-K 1 dp821156k.htm F0RM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2017 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Sai
October 30, 2017	SC TO-C	Novartis SC TO-C SC TO-C 1 a2233665zscto-c.htm SC TO-C QuickLinks - Click here to rapidly navigate through this document SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Advanced Accelerator Applications S.A. (Name of Subject Company) Novartis AG (Name of Filing Persons (Offerors)) American Deposit
October 30, 2017	EX-99.1	MEDIA RELEASE · COMMUNIQUE AUX MEDIAS · MEDIENMITTEILUNG Exhibit (a)(5)(A) Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.
September 29, 2017	EX-99.1	Advanced Accelerator Applications Announces European Approval of Lutetium (177Lu) Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors Completes First Theragnostic Radiopharmaceutical Pairing in Oncology EXHIBIT 99.1 PRESS RELEASE Advanced Accelerator Applications Announces European Approval of Lutetium (177Lu) Oxodotreotide (Lutathera?) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors Completes First Theragnostic Radiopharmaceutical Pairing in Oncology September 29, 2017, Saint-Genis-Pouilly, France - Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an internat
September 29, 2017	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp811126k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2017 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 S
September 6, 2017	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp802966k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2017 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 S
September 6, 2017	EX-99.1	Advanced Accelerator Applications Announces First Patient in Bridging Study in Japan for Lutetium Lu 177 Dotatate* (Lutathera®) Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Announces First Patient in Bridging Study in Japan for Lutetium Lu 177 Dotatate* (Lutathera?) September 6, 2017, Saint-Genis-Pouilly, France - Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine (MNM), today announced that the first patient has been treated
August 31, 2017	EX-99.1	Advanced Accelerator Applications Reports 32% Sales Growth for Second Quarter 2017 Positive CHMP Opinion for Lutetium Lu 177 Dotatate* (Lutathera®) for GEP-NETS FDA Acknowledged Receipt and Completeness of NDA Resubmission for Lutetium Lu 177 Dotatat Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Reports 32% Sales Growth for Second Quarter 2017 Positive CHMP Opinion for Lutetium Lu 177 Dotatate* (Lutathera?) for GEP-NETS FDA Acknowledged Receipt and Completeness of NDA Resubmission for Lutetium Lu 177 Dotatate* (Lutathera?) and Provided PDUFA Date of January 26, 2018 Second Quarter 2017 Highlights: ? Sales for the second quarter
August 31, 2017	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2017 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Addr
August 31, 2017	EX-99.2	Advanced Accelerator Applications S.A. 20 rue Rudolf Diesel 01630 Saint Genis Pouilly IFRS CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Six months and three months ended June 30, 2017 and 2016 EX-99.2 3 dp79915ex9902.htm EXHIBIT 99.2 Exhibit 99.2 Advanced Accelerator Applications S.A. Advanced Accelerator Applications S.A. 20 rue Rudolf Diesel 01630 Saint Genis Pouilly IFRS CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Six months and three months ended June 30, 2017 and 2016 1 Advanced Accelerator Applications S.A. CONDENSED CONSOLIDATED STATEMENTS OF INCOME Six Months and three M
August 28, 2017	EX-99.1	Advanced Accelerator Applications Announces New Prescription Drug User Fee Act (PDUFA) date of January 26, 2018, for Lutetium Lu 177 Dotatate (Lutathera®) Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Announces New Prescription Drug User Fee Act (PDUFA) date of January 26, 2018, for Lutetium Lu 177 Dotatate (Lutathera?) August 28, 2017, Saint-Genis-Pouilly, France - Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine (MNM), today announced that the US Foo
August 28, 2017	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp798976k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2017 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Sain
July 27, 2017	EX-99.1	Advanced Accelerator Applications Completes Resubmission of NDA for Lutetium Lu 177 Dotatate (Lutathera®) to FDA Conference Call Today at 5:00 p.m. ET Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Completes Resubmission of NDA for Lutetium Lu 177 Dotatate (Lutathera?) to FDA Conference Call Today at 5:00 p.m. ET July 27, 2017, Saint-Genis-Pouilly, France - Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine (MNM), today announced that the resubmission
July 27, 2017	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2017 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Addres
July 24, 2017	EX-99.1	Advanced Accelerator Applications Announces Positive CHMP Opinion Recommending Approval of Lutetium 177Lu Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors EX-99.1 2 dp78536ex9901.htm EXHIBIT 99.1 Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Announces Positive CHMP Opinion Recommending Approval of Lutetium 177Lu Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors July 21, 2017, Saint-Genis-Pouilly, France - Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international spe
July 24, 2017	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp785366k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2017 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint
July 17, 2017	EX-13.2	CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.2 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of Advanced Accelerator Applications S.A. (the ?Company?) for the fiscal year ended December 31, 2016 (the ?Report?), I, Heinz M?u
July 17, 2017	EX-12.1	CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Stefano Buono, certify that: 1. I have reviewed this annual report on Form 20-F of Advanced Accelerator Applications S.A.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the stat
July 17, 2017	EX-12.2	CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.2 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Heinz M?usli, certify that: 1. I have reviewed this annual report on Form 20-F of Advanced Accelerator Applications S.A.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the state
July 17, 2017	20-F/A	Advanced Accelerator Applications S.A FORM 20-F/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F/A Amendment No. 1 (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
July 17, 2017	EX-15.1	Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statements (No. 333-219269 and No. 333-213733) on Forms S-8 of Advanced Accelerator Applications S.A of our reports dated March 29, 2017, with respect to the consolidated statements of financial position of Advanced Accelerator Applications S.A. and its subsidiarie
July 17, 2017	EX-13.1	CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of Advanced Accelerator Applications S.A. (the ?Company?) for the fiscal year ended December 31, 2016 (the ?Report?), I, Stefano B
July 17, 2017	CORRESP	Advanced Accelerator Applications S.A ESP New York Menlo Park Washington DC S?o Paulo London Paris Madrid Tokyo Beijing Hong Kong John G.
July 13, 2017	EX-99.1	ADVANCED ACCELERATOR APPLICATIONS S.A. Company with a share capital of 8,817,765.70 Euros Head Office: 20, rue Diesel, 01630 Saint Genis Pouilly, France 441 417 110 RCS Bourg en Bresse (the « Company ») SUBSCRIPTION FORM Exhibit 99.1 ADVANCED ACCELERATOR APPLICATIONS S.A. Company with a share capital of 8,817,765.70 Euros Head Office: 20, rue Diesel, 01630 Saint Genis Pouilly, France 441 417 110 RCS Bourg en Bresse (the ? Company ?) SUBSCRIPTION FORM 1. MODALITIES FOR WARRANTS 2017 ISSUANCE As per the first resolution of the Extraordinary Shareholder Meeting held on May 24, 2017, the Company?s shareholders have de
July 13, 2017	S-8	Advanced Accelerator Applications S.A FORM S-8 As filed with the Securities and Exchange Commission on July 13, 2017 Registration No.
May 31, 2017	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2017 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Address
May 31, 2017	EX-99.2	Advanced Accelerator Applications S.A. 20 rue Rudolf Diesel 01630 Saint Genis Pouilly IFRS CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Three months ended March 31, 2017 and 2016 EX-99.2 3 dp76734ex9902.htm EXHIBIT 99.2 Exhibit 99.2 Advanced Accelerator Applications S.A. Advanced Accelerator Applications S.A. 20 rue Rudolf Diesel 01630 Saint Genis Pouilly IFRS CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Three months ended March 31, 2017 and 2016 1 Advanced Accelerator Applications S.A. CONDENSED CONSOLIDATED STATEMENTS OF INCOME Three Months ended March 31, 2017 an
May 31, 2017	EX-99.1	Advanced Accelerator Applications Reports 21% Sales Growth for First Quarter 2017 On Track to Resubmit NDA for lutetium Lu 177 dotatate (Lutathera®) to FDA in Mid-2017 NETSPOT® Unit Sales per Month Jump 140% During First Quarter EX-99.1 2 dp76734ex9901.htm EXHIBIT 99.1 Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Reports 21% Sales Growth for First Quarter 2017 On Track to Resubmit NDA for lutetium Lu 177 dotatate (Lutathera®) to FDA in Mid-2017 NETSPOT® Unit Sales per Month Jump 140% During First Quarter First Quarter 2017 Highlights: · Advanced preparations for resubmission of lutetium Lu 177 dotatate (Lu
May 30, 2017	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2017 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Address
May 30, 2017	EX-99.1	Advanced Accelerator Applications and Blue Earth Diagnostics Announce European Manufacturing and Distribution Agreements for Axumin™ (Fluciclovine (18F)) for PET Imaging of Recurrent Prostate Cancer Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications and Blue Earth Diagnostics Announce European Manufacturing and Distribution Agreements for Axumin? (Fluciclovine (18F)) for PET Imaging of Recurrent Prostate Cancer Saint-Genis-Pouilly, France and Oxford, UK ? May 30, 2017 ? Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA), an international specialist in Molecular Nuclear Medic
May 30, 2017	EX-99.1	ADVANCED ACCELERATOR APPLICATIONS Société Anonyme au capital de 8,817,765.70 Euros Siège Social: 20, rue Diesel – 01630 SAINT GENIS POUILLY RCS BOURG-EN-BRESSE 441 417 110 Interpretation of the original French text for the convenience of AAA Sharehol EX-99.1 2 dp76676ex9901.htm EXHIBIT 99.1 Exhibit 99.1 ADVANCED ACCELERATOR APPLICATIONS Société Anonyme au capital de 8,817,765.70 Euros Siège Social: 20, rue Diesel – 01630 SAINT GENIS POUILLY RCS BOURG-EN-BRESSE 441 417 110 Interpretation of the original French text for the convenience of AAA Shareholders Agenda of the annual shareholder meeting at May 24, 2017 which takes place at the AAA headq
May 30, 2017	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp766766k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2017 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint G
May 25, 2017	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2017 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Address
May 25, 2017	EX-99.1	Advanced Accelerator Applications Appoints Christine Mikail to Board of Directors Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Appoints Christine Mikail to Board of Directors Saint-Genis-Pouilly, France ? May 25, 2017 ? Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine (MNM), today announced that Christine Mikail, J.D. has joined the Company?s board of directors as an independent
May 18, 2017	EX-99.1	Advanced Accelerator Applications Receives 2017 Industry Innovation Award from National Organization for Rare Disorders for NETSPOT®, a Diagnostic Drug for Neuroendocrine Tumors Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Receives 2017 Industry Innovation Award from National Organization for Rare Disorders for NETSPOT?, a Diagnostic Drug for Neuroendocrine Tumors Saint-Genis-Pouilly, France ? May 18, 2017 ? Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine (MNM), today anno
May 18, 2017	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2017 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Address
March 30, 2017	EX-99.1	Advanced Accelerator Applications Signs Strategic Supply Agreement with University of Missouri for Lutetium 177 Strengthens Global Supply Chain for Lead Investigational Product Lutetium Lu 177 Dotatate (Lutathera®) and Future Lu-177 Products Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Signs Strategic Supply Agreement with University of Missouri for Lutetium 177 Strengthens Global Supply Chain for Lead Investigational Product Lutetium Lu 177 Dotatate (Lutathera?) and Future Lu-177 Products Saint-Genis-Pouilly, France ? March 30, 2017 ? Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an intern
March 30, 2017	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2017 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Addre
March 29, 2017	EX-4.6	2 September 2016 LETTER OF AGREEMENT Exhibit 4.6 2 September 2016 LETTER OF AGREEMENT Stefano Buono Chairman and CEO Advance Accelerator Applications USA, Inc. The Empire State Building 350 Fifth Avenue, Suite 6902 69th Floor New York NY 10118 United States of America Chief Executive Officer Advance Accelerator Applications 20 rue Diesel, 01630 Saint-Genis-Pouilly France Dear Mr. Buono: This Letter of Agreement is intended to documen
March 29, 2017	20-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC
March 29, 2017	EX-4.7	8 November 2016 Exhibit 4.7 8 November 2016 Stefano Buono Chief Executive Officer Advance Accelerator Applications 20 rue Diesel, 01630 Saint-Genis-Pouilly France Dear Mr. Buono: In response to a request from your Head of Legal C?cile Meynet, this letter is intended to clarify the status of the Clinical Services Agreement (the ?Agreement?) between Advanced Accelerator Applications (hereafter to be referred to as
March 29, 2017	EX-12.2	CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.2 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Heinz M?usli, certify that: 1. I have reviewed this annual report on Form 20-F of Advanced Accelerator Applications S.A.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the state
March 29, 2017	EX-13.2	CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.2 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of Advanced Accelerator Applications S.A. (the ?Company?) for the fiscal year ended December 31, 2016 (the ?Report?), I, Heinz M?u
March 29, 2017	EX-13.1	CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of Advanced Accelerator Applications S.A. (the ?Company?) for the fiscal year ended December 31, 2016 (the ?Report?), I, Stefano B
March 29, 2017	EX-15.1	Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statement (No. 333-213733) on Form S-8 of Advanced Accelerator Applications S.A of our reports dated March 29, 2017, with respect to the consolidated statements of financial position of Advanced Accelerator Applications S.A. and its subsidiaries as of December 31,
March 29, 2017	EX-1.1	ADVANCED ACCELERATOR APPLICATIONS A limited company with a capital of €8,817,765.70 Registered office: 20, rue Diesel, 01630 Saint Genis Pouilly BOURG EN BRESSE Trade and Companies Register no. 441 417 110 ARTICLES OF ASSOCIATION Entry in Force on Ma EX-1.1 2 dp74300ex0101.htm EXHIBIT 1.1 Exhibit 1.1 ADVANCED ACCELERATOR APPLICATIONS A limited company with a capital of €8,817,765.70 Registered office: 20, rue Diesel, 01630 Saint Genis Pouilly BOURG EN BRESSE Trade and Companies Register no. 441 417 110 ARTICLES OF ASSOCIATION Entry in Force on March 3, 2017 SECTION I – LEGAL FORM, PURPOSE, CORPORATE NAME, REGISTERED OFFICE AND DURATION 3 Artic
March 29, 2017	EX-12.1	CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Stefano Buono, certify that: 1. I have reviewed this annual report on Form 20-F of Advanced Accelerator Applications S.A.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the stat
March 23, 2017	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2017 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Addre
March 23, 2017	EX-99.1	Advanced Accelerator Applications Reports 23% Sales Growth for Fiscal 2016; Continued NETSPOT® Launch Success On Track to Resubmit NDA for lutetium Lu 177 dotatate (Lutathera®) to FDA in Mid-2017 Conference Call Today at 10:00 a.m. ET PRESS RELEASE Advanced Accelerator Applications Reports 23% Sales Growth for Fiscal 2016; Continued NETSPOT? Launch Success On Track to Resubmit NDA for lutetium Lu 177 dotatate (Lutathera?) to FDA in Mid-2017 Conference Call Today at 10:00 a.
March 15, 2017	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp740346k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2017 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint
March 15, 2017	EX-99.1	Advanced Accelerator Applications to Announce Full-Year 2016 Financial Results on March 23 Conference Call at 10:00 a.m. ET EX-99.1 2 dp74034ex9901.htm EXHIBIT 99.1 Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications to Announce Full-Year 2016 Financial Results on March 23 Conference Call at 10:00 a.m. ET Saint-Genis-Pouilly, France – March 15, 2017 – Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or the “Company”), an international specialist in Molecular Nuclear Medicine (MNM), today announced t
March 6, 2017	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2017 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Addre
March 6, 2017	EX-99.1	Advanced Accelerator Applications Announces Presentation of Quality of Life Findings from NETTER-1 Phase III Study at ENETS Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Announces Presentation of Quality of Life Findings from NETTER-1 Phase III Study at ENETS Saint-Genis-Pouilly, France ? March 6, 2017 ? Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (?AAA? or the ?Company?), an international specialist in Molecular Nuclear Medicine (MNM), today announced that quality of life findings from the pivo
March 1, 2017	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2017 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Addre
March 1, 2017	EX-99.1	Advanced Accelerator Applications Announces Addition of NETSPOT® to National Comprehensive Cancer Network® Guidelines for Evaluation of NETs Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Announces Addition of NETSPOT? to National Comprehensive Cancer Network? Guidelines for Evaluation of NETs Saint-Genis-Pouilly, France ? March 1, 2017 ? Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (?AAA? or the ?Company?), an international specialist in Molecular Nuclear Medicine (MNM), today announced that its product NETSPOT?
February 14, 2017	SC 13G/A	AAAP / Advanced Accelerator Applications S.A / Fin Posillipo S.p.A. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Advanced Accelerator Applications S.A. (Name of Issuer) Ordinary Shares, nominal value €.10 per share, and American Depositary Shares, each representing two (2) Ordinary Shares (Title of Class of Securities) 00790T100** (CUSIP Number) December 31, 2016
February 14, 2017	SC 13G/A	Advanced Accelerator Applications S.A SC 13G/A (Passive Acquisition of More Than 5% of Shares) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Advanced Accelerator Applications S.A. (Name of Issuer) Ordinary Shares, nominal value ?.10 per share, and American Depositary Shares, each representing two (2) Ordinary Shares (Title of Class of Securities) 00790T100** (CUSIP Number) December 31, 2016
February 14, 2017	EX-99.1	AGREEMENT AGREEMENT Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13G is being filed on behalf of each of the undersigned.
February 8, 2017	SC 13G/A	AAAP / Advanced Accelerator Applications S.A / Buono Stefano - FORM SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. 1 Advanced Accelerator Applications S.A. (Name of Issuer) Ordinary Shares, par value €0.10 per share (Title of Class of Securities) 00790T100* (CUSIP Number) (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru
February 8, 2017	SC 13G/A	Advanced Accelerator Applications S.A FORM SC 13G/A (Passive Acquisition of More Than 5% of Shares) SC 13G/A 1 dp72677sc13ga.htm FORM SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. 1 Advanced Accelerator Applications S.A. (Name of Issuer) Ordinary Shares, par value €0.10 per share (Title of Class of Securities) 00790T100* (CUSIP Number) (Date of Event which Requires Filing of this Statement) Ch
February 7, 2017	SC 13G	AAAP / Advanced Accelerator Applications S.A / PRICE T ROWE ASSOCIATES INC /MD/ - AAAP AS OF 12/31/2016 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) ADVANCED ACCELERATOR APPLICATIONS S.A. (Name of Issuer) ORDINARY SHARES AMERICAN DEPOSITARY SHARES (Title of Class of Securities) 00790T100* (CUSIP Number) December 31, 2016 (Date of Event which Requires Filing of Statement) Check the appropriate box t
January 12, 2017	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2017 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Add
January 12, 2017	EX-99.1	Advanced Accelerator Applications Announces New England Journal of Medicine Publication of Lutathera® NETTER-1 Phase III Results PRESS RELEASE Advanced Accelerator Applications Announces New England Journal of Medicine Publication of Lutathera? NETTER-1 Phase III Results Saint-Genis-Pouilly, France ? January 12, 2017 ? Advanced Accelerator Applications S.
January 9, 2017	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2017 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Add
January 9, 2017	EX-99.1	Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera® NDA PRESS RELEASE Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera? NDA Saint-Genis-Pouilly, France ? January 9, 2017 ? Advanced Accelerator Applications S.
January 4, 2017	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2017 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Add
January 4, 2017	EX-99.1	Advanced Accelerator Applications to Present at 35th Annual J.P. Morgan Healthcare Conference EXHIBIT 99.1 PRESS RELEASE Advanced Accelerator Applications to Present at 35th Annual J.P. Morgan Healthcare Conference Saint-Genis-Pouilly, France ? January 4, 2017 ? Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (?AAA? or ?the Company?), an international specialist in Molecular Nuclear Medicine (?MNM?), today announced that the company is scheduled to present at the 35th Annual J.P. Morg
December 21, 2016	EX-99.1	Advanced Accelerator Applications Receives Complete Response Letter from FDA for Lutathera®, an Investigational Treatment for Neuroendocrine Tumors No Additional Clinical Studies Requested PRESS RELEASE Advanced Accelerator Applications Receives Complete Response Letter from FDA for Lutathera?, an Investigational Treatment for Neuroendocrine Tumors No Additional Clinical Studies Requested Saint-Genis-Pouilly, France ? December 21, 2016 ? Advanced Accelerator Applications S.
December 21, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Ad
December 15, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Ad
December 15, 2016	EX-99.1	Advanced Accelerator Applications Announces European Commission Approval of SomaKit TOC™ Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Announces European Commission Approval of SomaKit TOC? Saint-Genis-Pouilly, France ? December 15, 2016 ? Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (?AAA? or ?the Company?), an international specialist in molecular nuclear medicine, today announced that following a positive opinion issued by the European Medicines Agency in Oct
December 8, 2016	EX-99.1	Advanced Accelerator Applications Announces CMS Pass-Through Reimbursement Code for its First FDA Approved Drug NETSPOT® Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Announces CMS Pass-Through Reimbursement Code for its First FDA Approved Drug NETSPOT? Saint-Genis-Pouilly, France ? December 8, 2016 ? Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (?AAA? or ?the Company?), an international specialist in Molecular Nuclear Medicine (?MNM?), today announced that the Centers for Medicare & Medicaid
December 8, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Ad
November 28, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Ad
November 23, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Ad
November 2, 2016	EX-99.1	Advanced Accelerator Applications Announces Swiss Marketing Authorization for Two PET Diagnostic Products Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Announces Swiss Marketing Authorization for Two PET Diagnostic Products Saint-Genis-Pouilly, France ? November 2, 2016 ? Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (?AAA? or ?the Company?), an international specialist in molecular nuclear medicine, announced today that the company has been granted marketing authorization in Swi
November 2, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Ad
October 17, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Add
October 17, 2016	EX-99.1	Advanced Accelerator Applications Announces Positive EMA Opinion on Application for SomaKit TOC PRESS RELEASE Advanced Accelerator Applications Announces Positive EMA Opinion on Application for SomaKit TOC Saint-Genis-Pouilly, France ? October 17, 2016 ? Advanced Accelerator Applications S.
October 11, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Add
October 11, 2016	EX-99.1	Advanced Accelerator Applications Announces Presentations on Lutathera® NETTER-1 Phase III and NeoBOMB1 at EANM PRESS RELEASE Advanced Accelerator Applications Announces Presentations on Lutathera? NETTER-1 Phase III and NeoBOMB1 at EANM Saint-Genis-Pouilly, France ? October 11, 2016 ? Advanced Accelerator Applications S.
October 6, 2016	424B1	3,947,369 American Depositary Shares Representing 7,894,738 Ordinary Shares Advanced Accelerator Applications S.A. (incorporated in France) 424B1 1 t1602362-424b1.htm FINAL PROSPECTUS TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(1) Registration No.: 333-213806 PROSPECTUS 3,947,369 American Depositary Shares Representing 7,894,738 Ordinary Shares Advanced Accelerator Applications S.A. (incorporated in France) This is a public offering of 3,947,369 American Depositary Shares, or ADS, representing 7,894,738 ordinary shares of Advanc
October 6, 2016	EX-99.1	Advanced Accelerator Applications S.A. Announces Pricing of $150 Million Public Offering of American Depositary Shares Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications S.A. Announces Pricing of $150 Million Public Offering of American Depositary Shares New York, NY? October 5, 2016 ? Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (?AAA? or the ?Company?), an international specialist in Molecular Nuclear Medicine (MNM), today announced the pricing of an underwritten public offering of 3,947,369 Am
October 6, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Add
October 5, 2016	F-1MEF	Advanced Accelerator Applications S.A FORM F-1 F-1MEF 1 t1602364f1mef.htm FORM F-1 As filed with the Securities and Exchange Commission on October 5, 2016 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact Name of Registrant as Specified in Its Charter) France 2834 Not Applicable (State or ot
October 4, 2016	EX-99.1	Advanced Accelerator Applications S.A. Announces Proposed Public Offering of American Depositary Shares Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications S.A. Announces Proposed Public Offering of American Depositary Shares Saint-Genis-Pouilly, France ? October 4, 2016 ? Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (?AAA? or the ?Company?), an international specialist in Molecular Nuclear Medicine (MNM), today announced that it has commenced an underwritten public offering of $125
October 4, 2016	F-1/A	As filed with the U.S. Securities and Exchange Commission on October 4, 2016 F-1/A 1 t1602309-f1a.htm AMENDMENT NO. 2 TO FORM F-1 TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on October 4, 2016 Registration No. 333-213806 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of Registrant as
October 4, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Add
October 3, 2016	F-1/A	Advanced Accelerator Applications S.A AMENDMENT NO. 1 TO FORM F-1 F-1/A 1 t1602347-f1a.htm AMENDMENT NO. 1 TO FORM F-1 As filed with the U.S. Securities and Exchange Commission on October 3, 2016 Registration No. 333-213806 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of Registrant as specified in Its c
October 3, 2016	CORRESP	Advanced Accelerator Applications S.A ESP New York Menlo Park Washington DC S?o Paulo London Paris Madrid Tokyo Beijing Hong Kong John G.
October 3, 2016	CORRESP	Advanced Accelerator Applications S.A ESP October 3, 2016 Re: Advanced Accelerator Applications S.A. Registration Statement on Form F-1 Registration No. 333-213806 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Dear Sir or Madam: In accordance with Rule 461 and Rule 430A under the Securities Act of 1933, as amended, Advanced Accelerator Applications S.A. (the ?Company?) hereby
October 3, 2016	CORRESP	Advanced Accelerator Applications S.A ESP October 3, 2016 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
September 26, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (A
September 26, 2016	F-1	As filed with the U.S. Securities and Exchange Commission on September 26, 2016 F-1 1 t1602271-f1.htm FORM F-1 TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on September 26, 2016 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of Registrant as specified in Its charter) Not Ap
September 26, 2016	EX-1.1	Advanced Accelerator Applications S.A. [_] Ordinary Shares (nominal value ?0.10 per share) Represented by [_] American Depositary Shares Underwriting Agreement Exhibit 1.1 Advanced Accelerator Applications S.A. [] Ordinary Shares (nominal value ?0.10 per share) Represented by [] American Depositary Shares Underwriting Agreement New York, New York [], 2016 J.P. Morgan Securities LLC Jefferies LLC Wells Fargo Securities, LLC As Representatives of the several Underwriters listed on Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York
September 22, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (A
September 22, 2016	EX-99.1	EMA Prematurely Announced Opinion on SomaKit TOC® Kit Application PRESS RELEASE EMA Prematurely Announced Opinion on SomaKit TOC? Kit Application Saint-Genis-Pouilly, France ? September 22, 2016 ? Advanced Accelerator Applications S.
September 21, 2016	S-8	Advanced Accelerator Applications S.A FORM S-8 As filed with the Securities and Exchange Commission on September 21, 2016 Registration No.
September 21, 2016	EX-99.1	ADVANCED ACCELERATOR APPLICATIONS S.A. Company with share capital of 7.855.621,10 Euros Head Office : 20, rue Diesel – 01630 Saint Genis Pouilly 441 417 110 RCS Bourg en Bresse (the « Company ») Exhibit 99.1 ADVANCED ACCELERATOR APPLICATIONS S.A. Company with share capital of 7.855.621,10 Euros Head Office : 20, rue Diesel – 01630 Saint Genis Pouilly 441 417 110 RCS Bourg en Bresse (the « Company ») SUBSCRIPTION FORM 1. MODALITIES FOR WARRANTS 2016 ISSUANCE As per the first resolution of the Extraordinary Shareholder Meeting held on May 26, 2016, the Company’s shareholders have delegated
September 21, 2016	EX-99.4	ADVANCED ACCELERATOR APPLICATIONS (AAA) S.A. with capital of ? 4.027.000 Headquarters at: 20, rue Diesel ? 01630 Saint Genis Pouilly Registered with RCS BOURG-EN-BRESSE 441 417 110 Free share plan for the benefit of designated AAA employees Terms and Exhibit 99.4 ADVANCED ACCELERATOR APPLICATIONS (AAA) S.A. with capital of ? 4.027.000 Headquarters at: 20, rue Diesel ? 01630 Saint Genis Pouilly Registered with RCS BOURG-EN-BRESSE 441 417 110 Free share plan for the benefit of designated AAA employees Terms and conditions Free translation of the original French text Introduction remarks Reminder of the previous employee share plan: ? Authorizati
September 21, 2016	EX-99.3	ADVANCED ACCELERATOR APPLICATIONS (AAA) S.A. with capital of €5.279.592,60 Headquarters at: 20, rue Diesel – 01630 Saint Genis Pouilly Registered with RCS BOURG-EN-BRESSE 441 417 110 Free share plan for the benefit of designated AAA employees Terms a EX-99.3 5 dp68694ex9903.htm EXHIBIT 99.3 Exhibit 99.3 ADVANCED ACCELERATOR APPLICATIONS (AAA) S.A. with capital of €5.279.592,60 Headquarters at: 20, rue Diesel – 01630 Saint Genis Pouilly Registered with RCS BOURG-EN-BRESSE 441 417 110 Free share plan for the benefit of designated AAA employees Terms and conditions Free translation of the original French text Introduction AAA shareholders decided
September 20, 2016	EX-99.1	Advanced Accelerator Applications Announces Revised EMA Review Timeline for Lutathera® PRESS RELEASE Advanced Accelerator Applications Announces Revised EMA Review Timeline for Lutathera? Saint-Genis-Pouilly, France ? September 20, 2016 ? Advanced Accelerator Applications S.
September 20, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp688106k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 S
September 16, 2016	EX-99.1	Advanced Accelerator Applications Announces Positive EMA Opinion on Application for SomaKit TOC Kit for Radiopharmaceutical Preparation of Gallium (Ga 68) Edotreotide for Gastroenteropancreatic Neuroendocrine Tumor Detection PRESS RELEASE Advanced Accelerator Applications Announces Positive EMA Opinion on Application for SomaKit TOC Kit for Radiopharmaceutical Preparation of Gallium (Ga 68) Edotreotide for Gastroenteropancreatic Neuroendocrine Tumor Detection Saint-Genis-Pouilly, France ? September 16, 2016 ? Advanced Accelerator Applications S.
September 16, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (A
September 12, 2016	EX-99.3	EX-99.3 Exhibit 99.3
September 12, 2016	EX-99.1	ADVANCED ACCELERATOR APPLICATIONS French Société Anonyme with a share capital of €7,855,621.10 Registered office: 20, rue Diesel – 01630 SAINT GENIS POUILLY 441 417 110 RCS BOURG-EN-BRESSE (The “Company”) Translation of the original French text for t Exhibit 99.1 ADVANCED ACCELERATOR APPLICATIONS French Soci?t? Anonyme with a share capital of ?7,855,621.10 Registered office: 20, rue Diesel ? 01630 SAINT GENIS POUILLY 441 417 110 RCS BOURG-EN-BRESSE (The ?Company?) Translation of the original French text for the convenience of AAA Shareholders Agenda of the extraordinary shareholders? meeting of September 26, 2016 1. Delegation of authority to
September 12, 2016	EX-99.1	Advanced Accelerator Applications S.A. 20 rue Rudolf Diesel 01630 Saint Genis Pouilly IFRS CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Six months and three months ended June 30, 2016 and 2015 EX-99.1 2 dp68594ex9901.htm EXHIBIT 99.1 Advanced Accelerator Applications SA Advanced Accelerator Applications S.A. 20 rue Rudolf Diesel 01630 Saint Genis Pouilly IFRS CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Six months and three months ended June 30, 2016 and 2015 1 CONDENSED CONSOLIDATED STATEMENTS OF INCOME Six Months and three Months ended June 30, 2016 and 2015 Three months Six mo
September 12, 2016	EX-99.2	EX-99.2
September 12, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (A
September 12, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (A
September 6, 2016	EX-99.1	Advanced Accelerator Applications Announces Two Phase II Studies Evaluating 99MrhAnnexin V-128 Imaging in Cardiovascular and Cardio-Oncology Indications at University of Ottawa Heart Institute and Ottawa Hospital EXHIBIT 99.1 PRESS RELEASE Advanced Accelerator Applications Announces Two Phase II Studies Evaluating 99MrhAnnexin V-128 Imaging in Cardiovascular and Cardio-Oncology Indications at University of Ottawa Heart Institute and Ottawa Hospital Saint-Genis-Pouilly, France ? September 6, 2016 ? Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (?AAA? or the ?Company?), an international specialist in
September 6, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (A
August 31, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Addr
August 31, 2016	EX-99.1	Advanced Accelerator Applications Reports 24.4% Sales Growth in the Second Quarter of 2016 Launches First U.S. Product and Continues Momentum with Pipeline EXHIBIT 99.1 PRESS RELEASE Advanced Accelerator Applications Reports 24.4% Sales Growth in the Second Quarter of 2016 Launches First U.S. Product and Continues Momentum with Pipeline Highlights: ? Sales for the second quarter of 2016 increased 24.4% compared to the second quarter of 2015 ? The U.S. Food and Drug Administration (FDA) granted Priority Review for Lutathera, with a Prescription Drug U
August 3, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) 6-K 1 dp677556k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Sain
August 3, 2016	EX-99.1	Advanced Accelerator Applications Announces First Administration of NETSPOTTM at Holy Name Medical Center Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Announces First Administration of NETSPOTTM at Holy Name Medical Center Saint-Genis-Pouilly, France - August 3, 2016 ? Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (?AAA? or ?the Company?), an international specialist in Molecular Nuclear Medicine (MNM), today announced the first administration of NETSPOTTM, a product recently ap
August 2, 2016	EX-99.1	Advanced Accelerator Applications Announces Clinical Trial Agreement with National Cancer Institute for Study of Lutathera in Patients with Inoperable Pheochromocytoma and Paraganglioma EX-99.1 2 dp67623ex9901.htm EXHIBIT 99.1 Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Announces Clinical Trial Agreement with National Cancer Institute for Study of Lutathera in Patients with Inoperable Pheochromocytoma and Paraganglioma Saint-Genis-Pouilly, France - August 2, 2016 – Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international spe
August 2, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Addr
July 27, 2016	EX-99.1	Advanced Accelerator Applications Announces Opening of First U.S. Manufacturing Facility; Preparation for Anticipated Lutathera Launch Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Announces Opening of First U.S. Manufacturing Facility; Preparation for Anticipated Lutathera Launch Saint-Genis-Pouilly, France - July 26, 2016 ? Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (?AAA? or ?the Company?), an international specialist in Molecular Nuclear Medicine (MNM), today announced the opening of its first U.S. ma
July 27, 2016	EX-99.8	Advanced Accelerator Applications preparing for Lutathera launch by scaling up production in Ivrea, Italy Company provides update on key European production site Exhibit 99.8 PRESS RELEASE Advanced Accelerator Applications preparing for Lutathera launch by scaling up production in Ivrea, Italy Company provides update on key European production site May 23, 2016, Saint-Genis-Pouilly, France - Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (?AAA? or ?the Company?), an international specialist in Molecular Nuclear Medicine (MNM), today announced that it
July 27, 2016	EX-99.3	Advanced Accelerator Applications Expands U.S. NETSPOTTM Supply Chain with Two Additional Radiopharmacy Networks Exhibit 99.3 PRESS RELEASE Advanced Accelerator Applications Expands U.S. NETSPOTTM Supply Chain with Two Additional Radiopharmacy Networks Saint-Genis-Pouilly, France - June 10, 2016 ? Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (?AAA? or ?the Company?), an international specialist in Molecular Nuclear Medicine (MNM), today announced that it has further strengthened its U.S. supply chain
July 27, 2016	EX-99.6	Advanced Accelerator Applications Expands its Presence in Germany with Strategic Acquisition of Two Production Sites EX-99.6 7 dp67434ex9906.htm EXHIBIT 99.6 Exhibit 99.6 PRESS RELEASE Advanced Accelerator Applications Expands its Presence in Germany with Strategic Acquisition of Two Production Sites May 27, 2016, Saint-Genis-Pouilly, France – Advanced Accelerator Applications S.A. (“AAA” or “the Company”) (Nasdaq: AAAP), an international specialist in Molecular Nuclear Medicine (“MNM”), announced today that AAA
July 27, 2016	EX-99.7	Advanced Accelerator Applications Appoints Francois Nader, M.D., to Board of Directors Healthcare Veteran Brings Expertise in Developing Innovative Therapies Exhibit 99.7 PRESS RELEASE Advanced Accelerator Applications Appoints Francois Nader, M.D., to Board of Directors Healthcare Veteran Brings Expertise in Developing Innovative Therapies May 26, 2016, Saint-Genis-Pouilly, France ? Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (?AAA? or ?the Company?), an international specialist in Molecular Nuclear Medicine (MNM), today announced that Franco
July 27, 2016	EX-99.2	Advanced Accelerator Applications Announces FDA Priority Review for Lutathera EX-99.2 3 dp67434ex9902.htm EXHIBIT 99.2 Exhibit 99.2 PRESS RELEASE Advanced Accelerator Applications Announces FDA Priority Review for Lutathera Saint-Genis-Pouilly, France - June 27, 2016 – Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in Molecular Nuclear Medicine (MNM), today announced that the U.S. Food and Drug Administration (FDA)
July 27, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Addres
July 27, 2016	EX-99.4	Cardinal Health to Prepare NETSPOTTM Doses for Advanced Accelerator Applications Preparing for the Launch of a Novel Kit for the Preparation of Gallium Ga 68 Dotatate for Neuroendocrine Tumor Detection Exhibit 99.4 PRESS RELEASE Cardinal Health to Prepare NETSPOTTM Doses for Advanced Accelerator Applications Preparing for the Launch of a Novel Kit for the Preparation of Gallium Ga 68 Dotatate for Neuroendocrine Tumor Detection Saint-Genis-Pouilly, France - June 9, 2016 ? Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (?AAA? or ?the Company?), an international specialist in Molecular Nuclea
July 27, 2016	EX-99.9	ITEL signs agreement with Advanced Accelerator Applications to commercialize F-18 radiopharmaceuticals in Southern Italy Exhibit 99.9 PRESS RELEASE ITEL signs agreement with Advanced Accelerator Applications to commercialize F-18 radiopharmaceuticals in Southern Italy May 18, 2016, Ruvo di Puglia, Italy ? ITEL, a leading manufacturer of medical imaging products and services, today announced that it has signed an agreement with Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (?AAA?) to manufacture and commercial
July 27, 2016	EX-99.5	Advanced Accelerator Applications Announces Expansion of Theranostic Pipeline with NeoBOMB1 Two Oral Presentations Featured at SNMMI Annual Meeting Exhibit 99.5 PRESS RELEASE Advanced Accelerator Applications Announces Expansion of Theranostic Pipeline with NeoBOMB1 Two Oral Presentations Featured at SNMMI Annual Meeting Saint-Genis-Pouilly, France ? June 7, 2016 ? Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (?AAA? or ?the Company?), an international specialist in Molecular Nuclear Medicine (MNM), today announced the expansion of its
June 10, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Addres
June 10, 2016	EX-99.1	ADVANCED ACCELERATOR APPLICATIONS Société Anonyme au capital de 7.855.621,10 Euros Siège Social : 20, rue Diesel – 01630 SAINT GENIS POUILLY RCS BOURG-EN-BRESSE 441 417 110 Interpretation of the original French text for the convenience of AAA Shareho Exhibit 99.1 ADVANCED ACCELERATOR APPLICATIONS Soci?t? Anonyme au capital de 7.855.621,10 Euros Si?ge Social : 20, rue Diesel ? 01630 SAINT GENIS POUILLY RCS BOURG-EN-BRESSE 441 417 110 Interpretation of the original French text for the convenience of AAA Shareholders Agenda of the annual shareholder meeting at May 26, 2016 Ordinary Shareholder Meeting: - Presentation of the report on the financia
June 2, 2016	EX-99.1	Advanced Accelerator Applications Announces FDA Approval of NETSPOTTM (Somakit-TATE), a Kit for the Preparation of Gallium Ga 68 Dotatate for Neuroendocrine Tumor Detection NETSPOTTM will be the new name for Somakit-TATE, a PET (Positron Emission Tom Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Announces FDA Approval of NETSPOTTM (Somakit-TATE), a Kit for the Preparation of Gallium Ga 68 Dotatate for Neuroendocrine Tumor Detection NETSPOTTM will be the new name for Somakit-TATE, a PET (Positron Emission Tomography) Diagnostic Saint-Genis-Pouilly, France ? June 2, 2016 ? Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (?AAA
June 2, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2, 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Add
June 1, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 31, 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Add
June 1, 2016	EX-99.1	Advanced Accelerator Applications Reports 29.6% Sales Growth in the First Quarter of 2016 Strengthens Commercial Platform for Launch of Somakit and Lutathera Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Reports 29.6% Sales Growth in the First Quarter of 2016 Strengthens Commercial Platform for Launch of Somakit and Lutathera First Quarter Highlights: ? Sales for the first quarter of 2016 increased 29.6% compared to the first quarter of 2015 ? Purchased 100% of the IDB Group to strengthen AAA?s commercial positioning of Lutathera ? Enter
April 29, 2016	EX-99.1	Advanced Accelerator Applications reports 26.8% sales growth in 2015 and continues to show significant clinical progress across both therapeutic and diagnostic platforms Company announces completed submission of Lutathera NDA and MAA to FDA and EMA r EX-99.1 2 dp65324ex9901.htm EXHIBIT 99.1 Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications reports 26.8% sales growth in 2015 and continues to show significant clinical progress across both therapeutic and diagnostic platforms Company announces completed submission of Lutathera NDA and MAA to FDA and EMA respectively 2015 Highlights · Reported a year-on-year increase in sales of 26.8% f
April 29, 2016	6-K	Advanced Accelerator Applications FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Addr
April 29, 2016	EX-1.1	ADVANCED ACCELERATOR APPLICATIONS A limited company with a capital of €7,855,621,10 Registered office: 20, rue Diesel, 01630 Saint Genis Pouilly BOURG EN BRESSE Trade and Companies Register no. 441 417 110 ARTICLES OF ASSOCIATION Entry in Force on No Exhibit 1.1 ADVANCED ACCELERATOR APPLICATIONS A limited company with a capital of ?7,855,621,10 Registered office: 20, rue Diesel, 01630 Saint Genis Pouilly BOURG EN BRESSE Trade and Companies Register no. 441 417 110 ARTICLES OF ASSOCIATION Entry in Force on November 17th, 2015 SECTION I ? LEGAL FORM, PURPOSE, CORPORATE NAME, REGISTERED OFFICE AND DURATION 3 Article 1 - Legal form of the company
April 29, 2016	EX-13.1	CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of Advanced Accelerator Applications S.A. (the “Company”) for the fiscal year ended December 31, 2015 (the “Report”), I, Stefano B
April 29, 2016	20-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC
April 29, 2016	EX-12.1	CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Stefano Buono, certify that: 1. I have reviewed this annual report on Form 20-F of Advanced Accelerator Applications S.A.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the stat
April 29, 2016	EX-12.2	CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.2 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Heinz Mäusli, certify that: 1. I have reviewed this annual report on Form 20-F of Advanced Accelerator Applications S.A.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the state
April 29, 2016	EX-13.2	CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.2 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of Advanced Accelerator Applications S.A. (the “Company”) for the fiscal year ended December 31, 2015 (the “Report”), I, Heinz Mäu
March 24, 2016	EX-99.1	Advanced Accelerator Applications Provides Lutathera Update Lutathera Expanded Access Program Now Open In U.S. to Eligible Patients NDA Filing to FDA and EMA Forthcoming Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Provides Lutathera Update Lutathera Expanded Access Program Now Open In U.S. to Eligible Patients NDA Filing to FDA and EMA Forthcoming March 23, 2016, Saint-Genis-Pouilly, France ? Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (?AAA? or ?the Company?), an international specialist in molecular nuclear medicine, today announced tha
March 24, 2016	6-K	Advanced Accelerator Applications FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Addr
February 25, 2016	6-K	Advanced Accelerator Applications FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (A
February 17, 2016	SC 13G	AAAP / Advanced Accelerator Applications S.A / Dompe Sergio Gianfranco Luigi Maria - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ADVANCED ACCELERATOR APPLICATIONS S.A. (Name of Issuer) Ordinary shares, nominal value € ..0 per share (Title of Class of Securities) F0R0DZ103 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate
February 16, 2016	SC 13G/A	AAAP / Advanced Accelerator Applications S.A / Fin Posillipo S.p.A. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G /A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Advanced Accelerator Applications S.A. (Name of Issuer) Ordinary Shares, nominal value €.10 per share, and American Depositary Shares, each representing two (2) Ordinary Shares (Title of Class of Securities) 00790T100** (CUSIP Number) December 31, 20
February 16, 2016	SC 13G	AAAP / Advanced Accelerator Applications S.A / Fin Posillipo S.p.A. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Advanced Accelerator Applications S.A. (Name of Issuer) Ordinary Shares, nominal value €.10 per share, and American Depositary Shares, each representing two (2) Ordinary Shares (Title of Class of Securities) 00790T100** (CUSIP Number) December 31, 2015 (D
February 10, 2016	SC 13G	AAAP / Advanced Accelerator Applications S.A / Levi Andrea Ruben Osvaldo - FORM SC 13G Passive Investment SC 13G 1 dp63375sc13g.htm FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Advanced Accelerator Applications S.A. (Name of Issuer) Ordinary Shares, par value €0.10 per share (Title of Class of Securities) 00790T100** (CUSIP Number) (Date of Event which Requires Filing of this Statement) Chec
February 9, 2016	SC 13G	AAAP / Advanced Accelerator Applications S.A / Buono Stefano - FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Advanced Accelerator Applications S.A. (Name of Issuer) Ordinary Shares, par value €0.10 per share (Title of Class of Securities) 00790T100** (CUSIP Number) (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the
January 27, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Ad
January 27, 2016	EX-99.1	Zevacor to produce SomaKit-TATE doses for AAA Novel kit for the preparation of Ga-68 DOTATATE for neuroendocrine tumor detection PRESS RELEASE \| Zevacor to produce SomaKit-TATE doses for AAA Novel kit for the preparation of Ga-68 DOTATATE for neuroendocrine tumor detection Dulles, Virginia, January 26, 2016 ? Zevacor Pharma, Inc.
January 11, 2016	EX-99.1	Advanced Accelerator Applications Signs Exclusive License Agreement With Johns Hopkins University to Develop PSMA Receptor Ligand in Prostate Cancer Company broadens pipeline with PSMA-SR6, which could be used to treat, image, monitor and stage prost EX-99.1 2 dp62494ex9901.htm EXHIBIT 99.1 Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Signs Exclusive License Agreement With Johns Hopkins University to Develop PSMA Receptor Ligand in Prostate Cancer Company broadens pipeline with PSMA-SR6, which could be used to treat, image, monitor and stage prostate cancer utilizing a clinical development strategy similar to Lutathera and Soma
January 11, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Ad
January 11, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Ad
January 11, 2016	EX-99.1	Advanced Accelerator Applications to Present New Data from Lutathera NETTER-1 Phase 3 Study at 2016 Gastrointestinal Cancer Symposium (ASCO GI) NETTER-1 abstract also selected for ASCO GI’s official Press Program PRESS RELEASE Advanced Accelerator Applications to Present New Data from Lutathera NETTER-1 Phase 3 Study at 2016 Gastrointestinal Cancer Symposium (ASCO GI) NETTER-1 abstract also selected for ASCO GI?s official Press Program 10 January 2016, Saint-Genis-Pouilly, France ? Advanced Accelerator Applications S.
January 7, 2016	EX-99.1	Advanced Accelerator Applications Acquires the IDB Group Transaction expands global supply chain in preparation for the commercial launch of Lutathera EX-99.1 2 dp62369ex9901.htm EXHIBIT 99.1 PRESS RELEASE Advanced Accelerator Applications Acquires the IDB Group Transaction expands global supply chain in preparation for the commercial launch of Lutathera 7 January 2016, Saint-Genis-Pouilly, France – Advanced Accelerator Applications S.A. (“AAA” or “the Company”) (Nasdaq: AAAP), an international specialist in Molecular Nuclear Medicine (“MNM”), a
January 7, 2016	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2016 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (Ad
December 10, 2015	EX-99.1	Advanced Accelerator Applications Reports 37% Growth in Sales for the Third Quarter of 2015 and 32% Growth in Sales for the first nine months of 2015 Exhibit 99.1 PRESS RELEASE Advanced Accelerator Applications Reports 37% Growth in Sales for the Third Quarter of 2015 and 32% Growth in Sales for the first nine months of 2015 Recent Highlights ? Reported an increase in year-over-year sales of approximately 37% for Q3 2015 compared to Q3 2014 ? Reported an increase in year-over-year sales of approximately 32% for the first nine months of 2015 com
December 10, 2015	EX-99.2	Advanced Accelerator Applications S.A. 20 rue Rudolf Diesel 01630 Saint Genis Pouilly UNAUDITED IFRS CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Three months and Nine months ended September 30, 2015 and 2014 Exhibit 99.2 Advanced Accelerator Applications SA Advanced Accelerator Applications S.A. 20 rue Rudolf Diesel 01630 Saint Genis Pouilly UNAUDITED IFRS CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Three months and Nine months ended September 30, 2015 and 2014 September 30, 2015 and 2014 UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME Three Months and Nine Months ended September 30, 201
December 10, 2015	6-K	Advanced Accelerator Applications S.A FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2015 Commission File Number: 001-36826 ADVANCED ACCELERATOR APPLICATIONS S.A. (Exact name of registrant as specified in its charter) 20 rue Diesel 01630 Saint Genis Pouilly, France (A
November 27, 2015	SC 13G	AAAP / Advanced Accelerator Applications S.A / HBM Healthcare Investments (Cayman) Ltd. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Advanced Accelerator Applications S.A. (Name of Issuer) Ordinary Shares, nominal value €.10 per share, and American Depositary Shares, each representing two (2) Ordinary Shares (Title of Class of Securities) 00790T100** (CUSIP Number) November 16, 2015 (D
November 12, 2015	424B1	4,688,000 American Depositary Shares Representing 9,376,000 Ordinary Shares Advanced Accelerator Applications S.A. (incorporated in France) t1502530-424b1 - none - 34.4184415s TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(1) Registration Statement No. 333-207223 PROSPECTUS 4,688,000 American Depositary Shares Representing 9,376,000 Ordinary Shares Advanced Accelerator Applications S.A. (incorporated in France) This is the initial public offering of American Depositary Shares, or ADSs, representing ordinary shares of Advanced Acc
November 6, 2015	CORRESP	Advanced Accelerator Applications S.A ESP November 6, 2015 Re: Advanced Accelerator Applications S.A. Amendment No. 1 to Registration Statement on Form F-1 Registration No. 333-207223 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Dear Sir or Madam: In accordance with Rule 461 and Rule 430A under the Securities Act of 1933, as amended, Advanced Accelerator Applications S.A. (th
November 6, 2015	CORRESP	Advanced Accelerator Applications S.A ESP November 6, 2015 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Advanced Accelerator Applications S.A. Registration Statement on Form F-1 (File No. 333-207223) Ladies and Gentlemen: As representatives of the several underwriters of Advanced Accelerator Applications S.A.?s (Advanced Accelerator Applications S.A. is referred to herein as the ?Company?) proposed publ

AAAP / Advanced Accelerator Applications S.A - Документы SEC, Годовой отчет, Доверенное заявление

Основная статистика

SEC Filings

SEC Filings (Chronological Order)